Nasal Myiasis: Clinical Evaluation, Extraction Protocols, And 2026 Management Standards

Nasal myiasis, historically referred to in clinical literature as peenash, is the parasitic infestation of the nasal cavities, paranasal sinuses, and adjacent soft tissues by the larvae (maggots) of dipterous flies. While uncommon in temperate and highly sanitized urban zones, it represents a destructive otolaryngic emergency primarily encountered in tropical and subtropical regions, rural agricultural settings, and among individuals with compromised mucosal integrity or impaired self-care abilities. The condition requires immediate clinical intervention, as unchecked larval burrowing can lead to rapid extensive cartilage destruction, orbital cellulitis, palatal perforation, and fatal intracranial invasion.

Understanding the specific dipteran etiology, recognizing the early stages of tissue destruction, and executing safe, systematic larval eradication remain the cornerstones of successful clinical management.

Etiological Agents and Pathophysiology of Sinonasal Infestation

The pathophysiology of nasal myiasis depends largely on whether the invading fly species is an obligate or facultative parasite. In obligate myiasis, the fly larvae require living host tissue to complete their developmental cycle. In facultative myiasis, female flies typically deposit eggs or first-instar larvae in decaying organic matter or necrotic wounds, though they readily exploit infected, crusting, or ulcerated living nasal mucosa.

Primary Dipteran Species

• Cochliomyia hominivorax (New World Screwworm): Endemic to parts of South America and isolated Caribbean areas, this obligate parasite poses extreme danger because larvae feed aggressively on viable, living muscle and neurovascular tissue rather than necrotic debris.
• Chrysomya bezziana (Old World Screwworm): Found across tropical Asia and sub-Saharan Africa, this species exhibits aggressive histolytic capabilities, producing severe sinus erosion, septal necrosis, and cavernous sinus thrombosis if left untreated.
• Lucilia sericata (Common Green Bottle Fly) and Calliphora vicina (Blue Bottle Fly): Primarily facultative parasites, these blowfly larvae typically feed on pre-existing necrotic material in the nasal vault, although their physical presence and enzymatic secretions induce significant secondary ulceration.
• Oestrus ovis (Sheep Botfly): Responsible for human ophthalmomyiasis and seasonal nasal myiasis in agricultural zones. The female deposits free-swimming first-stage larvae directly into the host's anterior nares while hovering, often without requiring pre-existing necrotic tissue.
• Wohlfahrtia magnifica: An obligate parasite distributed across the Mediterranean basin, Central Asia, and Eastern Europe, known for deep, destructive tissue cavitation within mucosal orifices.

Predisposing Risk Factors

Healthy, intact sinonasal ciliated respiratory epithelium is inherently resistant to opportunistic larval colonization. However, mechanical or biological disruptions to this barrier create an opportunistic environment. The predominant predisposing conditions encountered in clinical practice include:

• Atrophic Rhinitis (Ozena): Mucosal atrophy, lack of mucociliary clearance, room-filling fetor, and thick, desiccated crust formation provide an attractive site for gravid female flies to deposit eggs.
• Uncontrolled Diabetes Mellitus: Hyperglycemia impairs neutrophil chemotaxis and fosters microvascular mucosal ischemia, often complicated by fungal co-infections.
• Leprosy (Hansen's Disease): Nasal septal anesthesia, cartilaginous resorption, and persistent dry ulceration leave patients unable to detect fly contact or early larval movements.
• Neurological and Cognitive Impairment: Advanced dementia, cerebrovascular accidents, prolonged intensive care hospitalization, or profound substance intoxication where normal defense reflexes and insect-shooing mechanisms are absent.
• Post-Surgical Open Cavities: Patients who have undergone radical maxillectomy, large sinonasal resections, or total laryngectomy with residual open stomas.

Clinical Staging and Diagnostic Stratification

Nasal myiasis exhibits an aggressive timeline. The destructive potential of the larvae stems from their cephalopharyngeal skeleton, armed with oral hooks that tear mucosal walls, combined with proteolytic enzymes that digest living collagen and elastin.

Stage 1: Incubation and Mucosal Irritation (Hours to Day 2) Mild nasal tickling, persistent sneezing, thin serosanguinous rhinorrhea, and moderate obstruction. Often misdiagnosed as acute viral rhinosinusitis. Stage 2: Active Tissue Invasion and Ulceration (Days 3 to 7) Intense facial pain, progressive epistaxis, profound malodor, sense of moving foreign bodies, marked soft tissue edema of the midface, and visualization of active maggots in the nasal vestibule. Stage 3: Extensive Structural Necrosis and Complications (Day 7+) Complete destruction of the quadrangular cartilage (saddle nose deformity), erosion of the hard palate, lacrimal system destruction, orbital cellulitis, osteomyelitis of facial bones, and intracranial extension.

Advanced Diagnostic Procedures

Clinical confirmation begins with direct anterior rhinoscopy, which often reveals necrotic debris, pooled blood, and moving larvae. However, anterior rhinoscopy alone severely underestimates the cranial depth of the infestation.

1. Rigid Nasal Endoscopy (0-degree and 30-degree scopes): Diagnostic evaluation using rigid endoscopy under topical decongestion is essential. Endoscopy reveals the full extent of the infestation within the middle meatus, sphenoethmoidal recess, nasopharynx, and Eustachian tube orifices.
2. Computed Tomography (CT) of the Paranasal Sinuses (Bone and Soft Tissue Windows): High-resolution axial and coronal CT imaging must be obtained immediately. CT scans map mucosal thickening, air-fluid levels, and, crucially, focal bony dehiscence of the cribriform plate, lamina papyracea, or skull base.
3. Magnetic Resonance Imaging (MRI): Indicated when intracranial invasion, cavernous sinus thrombosis, or orbital apex syndrome is suspected based on cranial nerve deficits or visual loss.

Comprehensive 2026 Treatment Protocols

The eradication of nasal myiasis demands a multi-tiered approach: mechanical evacuation of the larvae, topical immobilization, systemic antiparasitic therapy, antimicrobial suppression of secondary infections, and definitive reconstruction of destroyed anatomical structures.

+----------------------------------------------------------------------------------------------------+ | CRITICAL MEDICAL ALERT | | Forced blind suctioning or non-immobilized mechanical pulling of live larvae risks tearing them, | | leaving retained cephalopharyngeal hooks inside mucosal pockets, causing severe secondary sepsis. | +----------------------------------------------------------------------------------------------------+

Stage 1: Larval Immobilization and Suffocation

Directly attempting to pluck active, mobile larvae with Hartmann or Takahashi forceps often drives the organisms deeper into inaccessible paranasal recesses, the Eustachian tube, or through dehiscent bone into the anterior cranial fossa. Topical asphyxiants and paralytic agents are applied prior to instrumentation:

• Turpentine and Liquid Paraffin Emulsion: A standard solution of pure medicinal turpentine oil mixed with liquid paraffin in a 1:4 ratio is instilled or applied on neurosurgical cottonoid pledgets for 10 to 15 minutes. The vapors block the respiratory spiracles of the larvae, paralyzing them and forcing them to release their mucosal hooks and migrate toward the anterior nasal vestibule.
• Dilute Chloroform-Water Formulations: When turpentine is contraindicated or unavailable, a solution of 10% to 20% chloroform in water or olive oil acts as a rapid anesthetic for dipteran larvae.
• Topical Ivermectin Irrigation: In modern protocols, off-label topical irrigations utilizing a 1% ivermectin solution have shown significant efficacy in paralyzing deeply seated larvae without inducing severe chemical irritation of the olfactory epithelium.

Stage 2: Endoscopic Mechanical Debridement

Once larvae are paralyzed or sufficiently slowed, the patient should undergo meticulous removal under direct endoscopic visualization:

1. Anesthesia: Local topical anesthesia (4% lidocaine with 1:100,000 epinephrine) is preferred in stable adults. General anesthesia with a secure cuffed endotracheal tube is mandatory in children, uncooperative adults, or patients with extensive palatal/skull base destruction to prevent aspiration of dislodged larvae into the bronchial tree.
2. Systematic Extraction: Using straight and angled grasping forceps (Blakesley, Tilley, or micro-cup forceps), every visible maggot is systematically withdrawn. Special attention must be paid to hidden recesses: the superior meatus, within ethmoid air cells, and along the sphenoid face.
3. Repeated Daily Scopes: Complete extraction in a single sitting is rare due to microscopic larvae and obscured pockets. Daily rigid nasal endoscopy must be continued until two consecutive daily examinations demonstrate zero residual larvae.

Stage 3: Systemic Pharmacotherapy

• Antiparasitic Therapy: Oral Ivermectin remains the pharmacological standard of care. Administered at a single oral dose of 200 micrograms per kilogram ($200\ \mu\text{g/kg}$), it may be repeated at 24 to 48 hours in severe cases involving invasive obligate parasites like Cochliomyia hominivorax. Ivermectin blocks glutamate-gated chloride channels in the larval nervous system, resulting in flaccid paralysis and death.
• Antibacterial Coverage: Larvae carry aggressive bacterial flora, predominantly Proteus mirabilis, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and various anaerobes. Initial empiric coverage requires intravenous broad-spectrum agents such as Amoxicillin-Clavulanate plus Ciprofloxacin, or Piperacillin-Tazobactam in severe hospital-acquired cases, adjusted based on cultured nasal swabs.
• Tetanus Prophylaxis: Nasal myiasis represents a contaminated, open soft-tissue wound. Intramuscular tetanus toxoid ($0.5\ \text{mL}$) must be administered alongside tetanus immunoglobulin if immunization history is uncertain or out of date.

Comparison of Clinical Treatment Modalities

The management of sinonasal myiasis requires balancing speed, invasiveness, tissue preservation, and pharmacological potency.

Management of Sequelae and Long-Term Prevention

Once the acute infestation is eradicated, treatment shifts to tissue healing, structural reconstruction, and mitigating predisposing vulnerabilities.

Structural Sequelae and Surgical Reconstruction

• Septal Perforation: Loss of the anterior cartilaginous septum creates a classic saddle nose deformity. Reconstruction should be delayed for at least 3 to 6 months post-eradication to confirm zero residual inflammation and adequate vascularization of adjacent mucosa. Complex mucosal advancement flaps or rib cartilage grafts may be required.
• Palatal Fistulae: Large oronasal communications require temporary acrylic obturator plates to preserve speech and prevent nasal regurgitation of fluids, followed by definitive repair using local mucosal rotation flaps or microvascular free tissue transfer (e.g., radial forearm free flap).
• Synechiae Formation: Extensive mucosal denudation results in aggressive intranasal scar bands (synechiae). Placement of non-absorbable silicone splints (e.g., Doyle splints) coated with antibiotic ointment for 7 to 10 days post-debridement reduces adhesion formation.

Mitigating Predisposing Mucosal Conditions

Patients with underlying atrophic rhinitis require long-term mucosal care to prevent repeat colonization:

1. Alkaline Nasal Douching: Daily high-volume nasal irrigations using warm solutions of sodium chloride, sodium bicarbonate, and sodium borate clear desiccated crusts, remove foul-smelling decomposing secretions, and maintain basic mucosal hydration.
2. Glycerin-Glucose Drops: Application of 25% glucose in glycerin drops inhibits the growth of proteolytic Klebsiella ozaenae organisms and reduces tissue desiccation.
3. Vector Barrier Protections: Patients with reduced sensorium, persistent tracheostomies, facial paralysis, or dementia must sleep under fine-mesh insect bed netting, particularly in tropical climates. Caregivers must be educated on daily nasal inspections and rapid reporting of persistent rhinorrhea or foul facial odors.

Frequently Asked Questions

What are the earliest symptoms of nasal myiasis?

The earliest symptoms include persistent unilateral or bilateral nasal tickling, frequent sneezing, unexplained low-grade epistaxis, and a rapidly worsening, foul-smelling serosanguinous discharge.

In the earliest stages, patients often suspect an aggressive foreign body or severe acute rhinosinusitis. However, the emergence of an intensely putrid odor within 48 to 72 hours, combined with localized facial puffiness and sensations of internal movement, distinguishes myiasis from standard infectious rhinitis.

Can maggots travel from the nose into the human brain?

Yes, untreated nasal myiasis can result in intracranial penetration through the erosion of the thin cribriform plate of the ethmoid bone or the roof of the sphenoid sinus.

Once the larvae breach the skull base, they can cause suppurative meningitis, subdural empyema, brain abscesses, and cavernous sinus thrombosis. This life-threatening progression highlights the urgent need for emergency contrast-enhanced CT or MRI imaging alongside immediate endoscopic removal upon diagnosis.

How is ivermectin dosed for nasal myiasis eradication?

Ivermectin is administered orally as a single weight-based dose of 200 micrograms per kilogram ($200\ \mu\text{g/kg}$), often combined with broad-spectrum antibiotics and topical suffocation agents.

In cases involving invasive species or heavy larval burdens where larvae remain active after 24 to 48 hours, a second identical dose of ivermectin is often administered. While ivermectin paralyzes larvae within tissues that surgical instruments cannot safely reach, dead larvae must still be systematically extracted using rigid endoscopy to prevent secondary abscess formation.

Is nasal myiasis contagious from person to person?

No, nasal myiasis cannot spread directly from person to person through casual contact, respiratory droplets, or physical touch.

Infestation occurs exclusively when a pregnant female fly of a specific dipteran species deposits eggs or living larvae directly into the nasal opening or onto nearby ulcerated tissue. However, multiple individuals living in the same environment may develop myiasis if sanitary conditions, high fly density, and shared predisposing health conditions (such as advanced atrophic rhinitis or neglect) are present.

What is the primary difference between obligate and facultative nasal myiasis?

Obligate myiasis is caused by dipteran fly species whose larvae require living host tissues to survive and develop, whereas facultative myiasis involves fly species whose larvae usually feed on decaying organic waste or dead tissue.

Clinically, obligate parasites (such as the New World Screwworm, Cochliomyia hominivorax) are far more dangerous because they actively tear into healthy, well-perfused cartilage, muscle, and nerve structures. Facultative parasites (such as Lucilia sericata) usually limit their activity to pre-existing necrotic debris and thick crusts, though their metabolic byproducts still cause substantial local inflammation and mucosal breakdown.

Clinical Summary and Urgent Recommendations

Nasal myiasis is an otolaryngic emergency that requires immediate medical intervention. Suspicion of infestation based on unexplained facial malodor, serosanguinous rhinorrhea, or direct visualization of dipteran larvae warrants emergency evaluation by an ear, nose, and throat (ENT) surgeon. Clinicians must forgo blind suctioning in favor of controlled topical immobilization, rigid diagnostic endoscopy, high-resolution CT imaging of the skull base, and weight-directed ivermectin therapy to prevent life-altering facial deformities or fatal intracranial complications.